These results demonstrate that PVR expression can be regulated by the SUMO pathway also in tumors other than MM, and suggest that PVR SUMOylation represents a more general strategy to prevent DNAM1-dependent tumor cell recognition and killing by NK cells. Here, PVR is linked to Miyoshi myopathy.